Minimally invasive endoscopic therapies for gastro-oesophageal reflux disease

Nasar Aslam, Andrea Telese, Vinay Sehgal, Rami Sweis, Laurence B Lovat, Rehan Haidry

ABSTRACT
The prevalence of the gastro-oesophageal reflux disease (GORD) in the western world is increasing. Uncontrolled GORD can lead to harmful long-term sequelae such as oesophagitis, stricture formation, Barrett’s oesophagus and oesophageal adenocarcinoma. Moreover, GORD has been shown to negatively impact quality of life. The current treatment paradigm for GORD consists of lifestyle modification, pharmacological control of gastric acid secretion or antireflux surgery. In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed which may play a role in bridging the unmet therapeutic gap between the medical and surgical treatment options. To ensure optimal patient outcomes following ARET, considered patient selection is crucial, which requires a mechanistic understanding of individual ARET options. Here, we will discuss the differences between ARETs along with an overview of the current evidence base. We also outline future research priorities that will help refine the future role of ARET.

INTRODUCTION
The prevalence of gastro-oesophageal reflux disease (GORD) in the western world is gradually increasing. This trend is reflective of the growing obesity epidemic compounded by an overall ageing population. Current data suggest a global prevalence for GORD that equates to roughly 14%. Long-term GORD can lead to oesophagitis, oesophageal strictures and ulceration. Furthermore 10%–15% of patients with chronic GORD develop Barrett’s oesophagus (BO). BO is considered a premalignant condition with nondysplastic BO having a 0.2%–0.5% risk of developing oesophageal adenocarcinoma per year. In addition to clinical consequences, GORD can negatively affect health-related quality of life (HRQL) and this has been demonstrated through several descriptive studies. A number of instruments have been developed and validated to enable assessment of quality of life metrics.

The current mainstay of treatment is spearheaded by lifestyle modification, followed by pharmacological treatment in the form of antacids, proton pump inhibitors and H2-Receptor blockers. Although most consider short term proton pump inhibitor (PPI) use to be safe, several studies have reported risks associated with long-term use. These include chronic kidney disease, acute interstitial nephritis, clostridium difficile infection, fracture risk, dementia and cardiovascular disease. Although some risks are contested, it is important to consider an individualised risk benefit analysis for each patient especially in a younger cohort where prolonged treatment is required.

Unfortunately, a significant proportion of patients have symptoms that remain refractory to medical therapy with a further cohort affected by side effects and pill burden. Here antireflux surgery (ARS) can be considered. ARS focuses on restoring the integrity of the lower oesophageal sphincter while undertaking concomitant hiatal hernia repair. The gold standard is laparoscopic fundoplication with patient satisfaction rates up to 95%.

ARS in well-selected patients with typical GORD-related symptoms is a very effective treatment but can be associated with complications in some patients. Early complications are usually very few and tend to be related to technical failure of the procedure. These include acute-onset dysphagia, usually from over tightening...
Endoscopy


Endoscopy of the crural repair, slipped wrap following profound retching and vomiting. These are indications for reoperation. Late complications include dysphagia, which usually improves over ensuing months, breakdown of the fundoplication leading to recurrent symptoms. Given some limitations of fundoplication, some patients may seek non-operative, less invasive approaches to reflux treatment.

In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed which may play a role in bridging the unmet therapeutic gap between the medical and surgical treatment. A number of these endoscopic options are no longer available either due to issues surrounding long-term efficacy or safety concerns, but lessons learnt from early devices undoubtedly influenced the development of current promising options that provide hope to fulfilling this unmet need (figure 1).

The endoscopic options available can broadly be split into radiofrequency (RF) devices, plications devices, injection techniques, mucosal resection techniques, ligation techniques and other. These will be discussed below.

PATIENT SELECTION FOR ARET
To ensure optimal outcomes following ARET careful patient selection is crucial. We suggest a standardised approach (figure 2) akin to that seen for patients undergoing ARS.

Pharmacological treatment trial
Prior to considering ARET patients should be treated with maximal medical therapy for at least a period of 6 months. This allows for an adequate treatment trial without subjecting patients to the associated long-term side effects of pharmacological antireflux therapy. Following adequate treatment trial ARET can be considered for those patients who have refractory symptoms.

Clinical assessment and patient discussion
As part of the workup for ARET, a clinical assessment should be undertaken taking into consideration patient fitness. It should be noted that some of the currently available devices are of large calibre and require pre-procedure balloon dilatation of the cricopharynx to allow for easy intubation.

Figure 1 Overview of historical, current and emerging therapy for GORD. Red=Historical therapies that are no longer available. Green=current therapies with evidence base (darker green=Stronger evidence base), grey=emerging/experimental therapies with limited evidence base or safety profile data. ARET, antireflux endoscopic therapies; ARMA, antireflux mucosal ablation; ARMS, antireflux mucosectomy; MASE, mucosal ablation and suturing at the oesophagogastric; MUSE, medigus ultrasonic surgical endostapler; PECC, peroral endoscopic cardial constriction; RAP, resection and plication; TIF, transoral incisionless fundoplication.

Figure 2 Patient selection process for ARET. ARET, antireflux endoscopic therapies.
Patients with atypical symptoms as a primary presentation such as cough without concomitant typical symptoms such as heartburn or regurgitation should not be selected for ARET.

Patients with high body mass index (BMI) are not recommended to undergo ARET and may be best served by undergoing bariatric procedures such as Roux-en-Y gastric bypass. Many current devices are not recommended for patients with a BMI >35 kg/m².

Finally, a thorough patient discussion is recommended explaining the merits and drawbacks of these novel treatment options and highlighting that surgical fundoplication is a time-tested effective treatment option for a large cohort of patients and currently remains the gold standard.

**Gastroscopy**

All patients should undergo a high-quality diagnostic gastroscopy. This allows for the detection of pathology that contravenes endoscopic intervention, such as large hiatal hernias, severe erosive oesophagitis (grade C/D), BO or stricturing disease.

We recommend thorough assessment of hiatal hernias with documentation of longitudinal and axial length and associated Hill grade. Patients with large hiatal hernias are not amenable to ARET and should be considered for ARS instead.

**Gastric emptying studies**

A multifactorial relationship exists between gastroparesis and GORD. Studies have demonstrated that the rate of proximal stomach emptying can impact postprandial oesophageal acid exposure and the number of reflux episodes per hour. The rate of gastric emptying can be evaluated through gastric emptying studies and should be undertaken as part of the ARET workup.

**Manometric testing**

Oesophageal manometry allows for the detection of motility disorders which can be misdiagnosed as GORD and subsequently lead to poor symptom response post ARET.

**Physiology studies**

The advent of gastrointestinal (GI) physiology has allowed us to further characterise and appreciate the phenotypic spectrum of GORD. Fifty per cent of patients with reflux symptoms have no evidence of erosive oesophagitis at endoscopy. Those with pathological oesophageal acid exposure on ambulatory pH testing without oesophagitis are considered to have non-erosive reflux disease (NERD). If there is positive reflux symptom association without pathological oesophageal acid exposure on physiological testing this is considered oesophageal hypersensitivity. Finally, if both acid exposure and symptom association are negative this is considered functional heartburn.

Prior to performing ARET objective physiology testing is warranted to confirm the presence and severity of GORD. This can be conducted via 24-hour catheter-based studies or via wireless capsule pH studies up to 96 hours. Those with functional heartburn and hypersensitive oesophagus should not be selected for ARET.

**RF TECHNIQUES**

**Stretta RF ablation (Restech, Houston, Texas, USA)**

The Stretta system is an endoscopic-assisted procedure that deploys RF thermal energy at several locations above, at and below the gastrooesophageal junction (GOJ). This is achieved through four radially placed needles at the distal end of the catheter (figure 3). Although the exact mechanism is unclear the delivery of thermal energy is postulated to cause tissue hypertrophy and remodelling, which results in improved barrier function and subsequent reduction in GORD symptoms.

Evidence base for Stretta

A 2014 systematic review and meta-analysis assessing evidence from controlled trials comparing Stretta therapy to sham or PPI found stretta to not be superior for improving physiological parameters, stopping PPI therapy or HRQL scores. Data were collated and reviewed from four trials which included a total of 165 patients. Three trials compared stretta to sham with one comparing stretta to PPI therapy. The society of American GI and endoscopic surgeons disagreed with the methodological approach and conclusions reached in the systematic review.

A further systematic review and meta-analysis conducted by a separate group in 2017 involving 2468 patients across 28 studies (4 randomised controlled trials, 23 cohort studies and 1 registry) in contrast found Stretta to significantly improve HRQL scores, PPI dependence at follow-up, as well as the incidence of erosive oesophagitis with reduced oesophageal acid exposure (p<0.001 across all comparisons).

Most of the evidence for Stretta is confined to trials undertaken over a 12-month period with limited high-quality long-term data. However, two single arm
trials have assessed the long-term efficacy of Stretta. Dughera et al evaluated outcomes post Stretta at 4 and 8 years in 26 patients finding 76.9% remaining off PPI, with a significant decrease in gastroesophageal reflux disease–health related quality of life (GERD-HRQL) scores (p=0.003) at the 8-year point.21

Another prospective study evaluated outcomes on 99 patients at 10 years and found 72% had improvement in GERD-HRQL scores with 41% remaining off PPI.22

Due to heterogeneous outcome data, the current 2021 American College of Gastroenterology (ACG) guidelines for the diagnosis and management of GORD do not recommend Stretta as an antireflux procedure.21

**PLICATION DEVICES**

**Esophyx**

Transoral incisionless fundoplication (TIF) was first introduced in 2006 as a non-surgical minimally invasive endoscopic option for treating reflux. TIF involves restoring a flap valve at the GOJ by pulling up the fundus and fastening it to oesophagus. The technique is most akin to the surgical gold standard of Nissen fundoplication in terms of anatomical alteration.24

The procedure is undertaken using the Esophyx device, which has undergone three revisions over time.24 The current iteration (TIF 2.0) involves reconstructing the gastro-oesophageal valve by creating a 2–3 cm 270° fundoplication, with plication performed above the Z line (Figure 4). The plication is achieved through the deployment of roughly 20 polypropylene non absorbable H shaped fasteners that have the equivalent strength of 3–0 sutures.25

TIF 2.0 is suitable for patients with Hiatal hernia’s equal or less than 2 cm in size with a Hill grade equal or less than 2. TIF is being evaluated as an option for patients with larger hiatal hernias as part of a concomitant TIF/laparoscopic hiatal hernia repair.26

**Evidence base for TIF**

Several randomised controlled trials have evaluated the role of TIF 2.0 in the treatment of GORD. The RESPECT study was a randomised placebo-controlled trial comparing TIF to sham. Patients were randomised to either TIF plus 6 months of placebo treatment (n=87) or Sham plus 6 months of omeprazole treatment (n=42). Thirty-six per cent of patients in the sham group had suffered early failure at 3 months in comparison to 11% who had undergone TIF (p=0.004). (Early failure was defined as moderate to severe regurgitation 12 weeks after intervention despite doubling of PPI treatment or placebo). Both arms of the trial showed improvement in GORD reported outcomes with TIF eliminating troublesome regurgitation in a greater proportion of patients (67% vs 45%, p=0.023).

Oesophageal pH improved following TIF. The mean per cent total time pH <4 went from 9.3% to 6.4% post TIF (p<0.001). The mean DeMeester score fell from 33.6 to 23.9 post-TIF (p<0.001). No improvement was observed following sham surgery.

Significant adverse events were reported in three patients who underwent TIF (abdominal pain, chest pain and musculoskeletal pain) and one who underwent the sham procedure (Nausea).27

The TEMPO trial was a randomised trial comparing TIF 2.0 using the EsophyX device, to PPI therapy. Sixty-three patients were randomised to either undergo TIF (n=40) or medical therapy with PPI (n=23). At 6 months follow-up, 97% of patients in the TIF group (off PPI) were no longer experiencing troublesome regurgitation as assessed by the reflux disease questionnaire vs 50% in the PPI group (RR 1.9, 95% CI 1.2 to 3.1, p=0.006). At 6 months, 90% of patients (35/39, 95% CI 0.76 to 0.97) in the TIF group had stopped taking PPI with 3% consuming PPI on demand (1/39, 95% CI <0.001 to 0.14) and 8% taking daily PPI (3/39, 95% CI 0.02 to 0.21). 54% (21/39) of patients in the TIF group had normalised oesophageal acid exposure in comparison to 52% (11/21) in the placebo arm (p=0.914). However, significant reductions were noted in the TIF group for number of reflux episodes, number of reflux episodes >5 min, %pH time less than 4 and DeMeester scores on 48 hour wireless Bravo testing (p<0.001).28 Long-term follow-up of the TEMPO trial has shown GERD-HRQL scores improving from 22.2 to 6.8 at 5 years (p<0.001).29

Håkansson et al conducted a double-blind sham-controlled trial with patients randomised to either TIF 2.0 (n=22) or sham (n=22). At 6-month follow-up, patients who had undergone TIF 2.0 had improved GORD symptom scores (p=0.005), whereas no significant change was noted in the sham arm. Ambulatory 24 hours pH monitoring revealed a significant reduction in total acid exposure time in the TIF 2.0 arm (7.8% pre-TIF vs 3.6% 6 months post-TIF, p=0.003), with no effect observed in the sham group (presham 13.1% vs 9.8% 6 months postsham, p=0.147).20

A 2018 systematic review and meta-analysis of 32 studies incorporating 1475 patients who underwent TIF revealed significant improvements in GERD-HRQL scores, gastro-oesophageal reflux symptom scale and reflux symptoms index post-TIF (p<0.001 for all). There was also a reduction in hiatal hernia size, in addition to discontinuation of PPI therapy.

---

**Figure 4** This figure demonstrates the steps for performing a 270°, 3 cm fundoplication with the Esophyx Z+ device.
post procedure. (p<0.001). Significant reduction in DeMeester scores was also observed (mean difference 10.22; p<0.001).31

Long-term outcomes of TIF 2.0 have been reported and show durable improvements in quality of life metrics, symptom response as well as reduction/interruption in PPI dosage up to 10 years.32-35

GERD-x
GERD-x (G-SURG, Germany) is an endoscopic device introduced in 2014 that allows for full thickness plication.36 Following intubation with the GERD-X device and an ultrathin gastrooscope, the GERD-X device is retroflexed, and the arms of the device are opened under direct endoscopic visualisation. A screw allows for tissue capture, and the arms of the device are closed enabling suture application via a stapler (figure 5).37 38

A recent single-centre, randomised, sham-controlled trial evaluated GERD-X in 70 PPI dependant patients who were randomised to either sham procedure or GERD-X in a 1:1 ratio. The primary endpoint was ≥50% improvement in GERD-HRQL score at 3 months. This was met by 65.7% of patients in the GERD-x group (2.9% in the sham group) (p<0.001). 62.8% of patients were PPI free at 12 months (11.4% in the sham group) (p<0.001). Furthermore, no serious adverse events (SAE)s were recorded in relation to the procedure.36

**Medigus ultrasonic surgical endostapler**
The Medigus ultrasonic surgical endostapler (MUSE) device contains a miniature camera, stapling anvil and ultrasound at the endoscopic tip. The device is retroflexed and retracted in the stomach with tissue clamped between the distal scope tip and body of the MUSE device. Ultrasound is used to assess tissue thickness prior to firing staples during plication.

### Table 1 Overview of current endoscopic therapies

<table>
<thead>
<tr>
<th>Device/technique</th>
<th>Advantage</th>
<th>Disadvantage</th>
<th>Reported adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stretta Radiofrequency</td>
<td>Single operator</td>
<td>Limited mechanistic data</td>
<td>Chest pain</td>
</tr>
<tr>
<td></td>
<td>Does not preclude future antireflux surgery</td>
<td>Heterogeneous evidence base with variable response rates</td>
<td>Erosive oesophagitis</td>
</tr>
<tr>
<td></td>
<td>Good safety profile</td>
<td>Limited improvement in physiological parameters</td>
<td>Gastroparesis</td>
</tr>
<tr>
<td>EsophyX Z+ Plication</td>
<td>Does not preclude future anti-reflux surgery</td>
<td>Two operator technique</td>
<td>Pneumothorax</td>
</tr>
<tr>
<td></td>
<td>Can be revised if required</td>
<td>Requires proprietary equipment</td>
<td>Perforation</td>
</tr>
<tr>
<td></td>
<td>Being evaluated as an option for concomitant laparoscopic HH repair (C-TIF) for larger HH</td>
<td>Large calibre device can make oesophageal intubation difficult</td>
<td>Bleeding</td>
</tr>
<tr>
<td>GERD-X Plication</td>
<td>Relatively short operating time</td>
<td>Two operator technique</td>
<td>Chest pain</td>
</tr>
<tr>
<td></td>
<td>Faster learning curve</td>
<td>Requires proprietary equipment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Limited long-term data</td>
<td></td>
</tr>
<tr>
<td>ARMS Mucosal resection</td>
<td>Does not require proprietary equipment</td>
<td>Steep learning curve</td>
<td>Dysphagia</td>
</tr>
<tr>
<td></td>
<td>Can be conducted without General anaesthetic (GA)</td>
<td>High risk of perforation and bleeding</td>
<td>Bleeding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non standardised technique</td>
<td>Perforation</td>
</tr>
<tr>
<td>ARMA Ablation</td>
<td>Does not require expensive proprietary equipment</td>
<td>Relatively new technique with limited evidence base</td>
<td>Dysphagia</td>
</tr>
<tr>
<td></td>
<td>Less technical than ARMS</td>
<td>Non standardised technique</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can be performed without GA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PECC/ARBM Ligation</td>
<td>Uses a technique and equipment that most gastroenterologists are well versed with</td>
<td>Limited data</td>
<td>Retrosternal discomfort</td>
</tr>
<tr>
<td></td>
<td>Shorter procedure time</td>
<td>Non standardised technique</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less technically challenging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MASE/RAP Suturing</td>
<td>Trialled in patients with altered anatomy post-surgery</td>
<td>Limited evidence base</td>
<td>Dysphagia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-standardised technique</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Steep learning curve</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Requires proprietary equipment</td>
<td></td>
</tr>
</tbody>
</table>

ARBM, antireflux band mucosectomy; ARMA, antireflux mucosal ablation; ARMS, antireflux mucosectomy; c-TIF, concomitant transoral incisionless fundoplication; MASE, mucosal ablation and suturing at the esophagogastric; PECC, peroral endoscopic cardial constriction; RAP, resection and plication.
A 2015 multicentre prospective study evaluated outcomes and safety data for MUSE in 66 patients. Six months postprocedure HRQL scores improved by >50% in 73% of patients with 64.6% no longer taking daily PPI therapy. Significant improvements in oesophageal acid exposure times were also noted (p<0.001). Eight AEs were reported in the initial 24 patients which included pneumothorax, oesophageal leak and GI haemorrhage. A protocol review led to future procedures requiring additional staples to reduce tension on individual staple sites. A 2019 prospective observational trial of MUSE found symptom improvement at 1-year postprocedure and 90% of patients stopping or halving PPI consumption.

**Endocinch**

Endocinch (Bard) was a suction-based plication device that applied sutures to the gastric mucosa. Long-term results failed to prove durability, presumably due to suture loss from lack of full thickness plication.

**NDO endoscopic plication system**

The NDO plication system allowed for full thickness plication of the gastric cardia to the oesophagus via a transmural suture. A 2006 randomised sham-controlled trial found significant improvements in QOL metrics, PPI dependence and oesophageal acid exposure with long-term durability. Due to the manufacturer financial difficulties this device is no longer available.

**INJECTION TECHNIQUES**

It has been postulated that submucosal injection of inert substances into the GOJ causes tissue remodelling at the lower oesophagus resulting in favourable outcomes for GORD by creating an enhanced physiological barrier to gastric acid. A number of injectable agents have been evaluated however many are no longer available due to poor long-term efficacy and/or safety concerns.

**MUCOSAL RESECTION**

**Antireflux mucosectomy**

Antireflux mucosectomy (ARMS) was born from a case report of a patient who underwent endoscopic resection for high-grade dysplastic BO. The resection margin extended to include a portion of the gastric cardia. The resultant scarring led to satisfactory reflux control up to 10 years postprocedure.

Inoue et al reported on findings from a case series on 10 GORD patients who underwent ARMS, finding improvements in DeMeester scores, acid exposure as well as Hill grade (3.2–1.2, p=0.0152). A recent prospective feasibility study has further explored ARMS as a treatment option. The group used a cap assisted EMR based technique for mucosectomy (ARMS-C) on 33 patients. A 6-month follow-up revealed 63% of patients no longer required antireflux medication with 30% reducing PPI dosage. GORD symptom scores had also significantly decreased. Improvements were also noted in pH studies, valve grade scores and GOJ distensibility as assessed by the endoFLIP device. Two patients required balloon dilatation for strictures and no SAEs were noted.

**LIGATION TECHNIQUES**

**Peroral endoscopic cardial constriction**

Peroral endoscopic cardial constriction (PECC) is a ligation based endoscopic technique. Although variations of the procedure have been studied the general premise involves ligating various locations across the GOJ and/or cardia with a combination of bands and/or clips. The resultant narrowing creates an enhanced physiological barrier for refluxate.

Hu et al evaluated PECC through a preliminary feasibility study involving 13 patients. Significant improvements were noted in GERD-HRQL and DeMeester scores (p<0.01), with no SAE. PECC-b is an adaptation of early PECC that uses solely bands for ligation deployed via a multiring ligator. A preliminary feasibility study involving PECC-b on 68 patients, found reduced symptom scores as assessed by the reflux diagnostic questionnaire (p<0.05) at 12 months with 77.9% of patients completely discontinuing PPI therapy, furthermore no SAE were reported.

**Antireflux band mucosectomy**

Band ligation of the cardia continues to be evaluated and a recent case series on four patients has found that band ligation can lead to significant resolution of symptoms with all patients discontinuing PPI 4 weeks postprocedure.

**OTHER TECHNIQUES**

**Mucosal ablation and suturing at the oesophagogastric junction**

The Apollo Overstitch endoscopic suturing system allows endoscopists to place full thickness sutures through the endoscope. This device has been used for several applications including defect closure, stent fixation and gastric bypass revisions.

Mucosal ablation and suturing at the oesophagogastric junction is a technique first reported by Han et al. Initial treatment with sutures suffered from a lack of durability due to suture loss. Modification of the technique by ablating the mucosa with APC prior to suture placement reduced suture loss. Out of 27 patients, 59% were able to discontinue PPI, with 14% reducing their daily dosage.

**Resection and plication anti-reflux method**

Benias et al evaluated the resection and plication (RAP) method in a pilot study of 10 patients. RAP involves creating a limited mucosectomy at the LOS, followed by plication with full thickness sutures at the mucosectomy site. All patients demonstrated significant improvements in reflux diagnostic questionnaire scores (p<0.01), with no SAE. Postprocedure, 60% of patients no longer required PPI therapy while 53% of patients no longer required PPI therapy while 53% of patients no longer required PPI therapy.
improvement in GERD-HRQL scores (p<0.0001) with eight patients discontinuing PPI use. One patient developed dysphagia related to stricture formation that required dilatation.61

Antireflux mucosal ablation
Antireflux mucosal ablation (ARMA) was developed by Inoue et al after trialling the technique on a patient with refractory GORD following the ARMS procedure. The technique involves ablating the gastric side of the cardia. Ablation is conducted up to the submucosa, with indigo carmine injection enabling appreciation of depth. A 2020 single arm pilot study found significant improvement in DeMeester scores and GERD-HRQL scores among 12 patients.62 A 2021 meta-analysis of non-randomised studies revealed similar levels of efficacy between ARMS and ARMA with acceptable safety profile.63

FUTURE RESEARCH PRIORITIES
The current body of evidence for ARET is associated with several limitations which has hampered widespread adoption into current treatment paradigms for GORD. Current ACG guidance only recommends TIF as a treatment option for patients with milder forms of GORD (<LA grade C esophagitis) who do not wish to undergo ARS. Due to it having a heterogeneous evidence base Stretta is not recommended. Other ARET are also not recommended due to a limited evidence base.

We propose several research priorities that will help refine the future role of ARET.

▲ High-quality randomised controlled trials
The placebo response for GORD can be as high as 50%.64 65 Sham-controlled trials can help address, but within this space such trials are limited in number with low participant numbers impacting generalisability of results.

▲ Trials comparing endoscopic therapy to the surgical gold standard
High-quality studies comparing endotherapy directly against Nissen fundoplication will help define the position of ARET within the current treatment paradigm.

▲ Head-to-head comparative studies
Head-to-head comparative trials are lacking but can help assess individual merits of ARETs and empower decision makers as well as inform future guidelines.

▲ Long-term data
GORD is chronic ailment therefore long-term data is vital for assessing the durability of ARETs. A significant proportion of trials in this field involve follow-up data to 12 months with limited high quality randomised data evaluating patient response at 5 years or above.

▲ Mechanistic data
Subjective improvement in reflux symptoms post endotherapy does not necessarily correlate with objective markers such as oesophageal acid exposure time or LOS pressure. It has previously been suggested that subjective improvement could be related to a disruption of sensory fibres, which results in decreased oesophageal sensitivity to gastric acid.60

CONCLUSIONS
The endoluminal treatment of GORD is an area of growing interest. Over the last two decades a number of devices and techniques have been developed and evaluated with many being withdrawn or not reaching mainstream popularity. The gastro-oesophageal junction is a complex zone that is still not anatomically or physiologically understood in its entirety.67

Currently, ARETs cannot be recommended over first-line ARS for many patients but do represent an alternative option for very high-risk surgical candidates with smaller hiatus hernias and milder forms of GORD. To ensure successful outcomes patient selection is key and a considered patient selection process is warranted. TIF 2.0 and Stretta have the largest body of evidence of all the ARETs, however, several novel therapies remain in the pipeline and require ongoing review (table 1). Future research needs to incorporate randomised controlled trials evaluating long-term outcomes, which will ultimately define future treatment algorithms for GORD.

Twitter Nasar Aslam @dr_nas_aslam and Laurence B Lovat @barrettsonline
Contributors NA conceptualised and drafted the initial manuscript. VS, RS, LBL, AT and RH revised critically for intellectual content. NA, VS, RS, LBL, AT and RH were involved in the review of the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests RH receives educational grants to support research infrastructure from Medtronic. Cook endoscopy (fellowship support), Pentax Europe, C2 therapeutics, Beamline diagnostic and Fractyl. VS receives honorarium for professional services from Pentax Europe, Medtronic, Astra Zeneca and Pharmacosmos. RS receives honoraria for running course and speaking at symposia for Medtronic, Johnson & Johnson, Falk Pharma, Medispar. HE is also on the advisory board for Johnson and Johnson and Falk Pharma.

Patient consent for publication Not applicable.
Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Nasar Aslam http://orcid.org/0000-0001-8105-1456

REFERENCES


37 10.1136/flgastro-2021-102343. Downloaded from http://fg.bmj.com/ on March 3, 2024 by guest. Protected by copyright.


a randomized, sham-controlled trial. Gastroenterology 2006;131:704–12.
65 Hogan WJ. Clinical trials evaluating endoscopic GERD treatments is it time for a moratorium on the clinical use of these procedures? Am J Gastroenterol 2006;101:437–9.